Key result
Continuous tafamidis cuts all-cause mortality ~57% vs delayed initiation in NAC stage I.
Why the study?
The National Amyloidosis Centre staging system stratifies ATTR-CM patients prognostically, but long-term mortality outcomes by NAC stage with tafamidis treatment were not fully evaluated.
Does continuous tafamidis treatment reduce all-cause and cardiovascular-related mortality across different NAC stages in patients with ATTR-CM compared to delayed treatment?
RCT (n=350)
Open-label (for the long-term extension)
Stratified by transthyretin (TTR) genotype (wild-type or variant) and NYHA class (I or II/III)
Does continuous tafamidis treatment reduce all-cause and cardiovascular-related mortality across different NAC stages in patients with ATTR-CM compared to delayed treatment?
Answers are grounded in this paper and cite their sources.
Continuous tafamidis treatment provides significant long-term mortality and hospitalization benefits in ATTR-CM, with the greatest and earliest benefits observed when initiated in early disease (NAC stage I).
Background The National Amyloidosis Centre (NAC) staging system is used to stratify patients with transthyretin amyloid cardiomyopathy (ATTR-CM) into prognostic categories.[1] Purpose This post hoc analysis evaluated all-cause and cardiovascular (CV)-related mortality in patients receiving tafamidis 80 mg or placebo by NAC stage at baseline in the phase 3 Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and its long-term extension (LTE) study.[2,3] Methods Patients in ATTR-ACT were randomised to tafamidis meglumine 80 mg, 20 mg, or placebo for 30 months, stratified by transthyretin (TTR) genotype (wild-type or variant) and NYHA class (I or II/III). Patients with an NT-proBNP <600 ng/l or eGFR <25 ml/min/1.73m² were excluded. After completing ATTR-ACT, patients could receive tafamidis 61 mg up to 60 months in the open-label LTE study. Heart transplant and cardiac mechanical assist device implantation were treated as death in the mortality assessments. Secondary analyses were change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical and overall summary (CS, OS) scores and frequency of all-cause and CV-related hospitalisations. Results Of 350 patients, 42%, 38% and 20% had NAC stage I, II and III at baseline, respectively. Patients at stage III tended to be older, more likely female, and with a variant TTR genotype vs those at a lower stage (Table). At the end of follow-up, all-cause mortality was consistently lower in patients continuously treated with tafamidis vs those who initially received placebo across NAC stages (I: 36% vs 61%; : 55% vs 74%; III: 69% vs 88%). The hazard ratio (HR [95% CI]) for all-cause mortality with continuous tafamidis treatment vs placebo to tafamidis was 0.43 (0.26-0.70; P<0.001), 0.51 (0.33-0.80; P=0.003) and 0.75 (0.44-1.29; P=0.298), for patients at stage I, II and III, respectively. Similar trends were observed in CV-related mortality at the end of follow-up, where HR (95% CI) for continuous tafamidis-treated patients at stage I, II and III was 0.39 (0.22-0.70; P=0.001), 0.51 (0.31-0.85; P=0.009) and 0.75 (0.42-1.33; P=0.320). The separation of survival curves was seen in the first few months of tafamidis treatment in patients at NAC stage I (Figure A). Such early separation was not seen in those at stage II or III. Starting from Month 18, statistically smaller declines in KCCQ-OS and CS scores were frequently observed in the continuous tafamidis vs placebo to tafamidis groups at stages I and II. Across NAC stages, all-cause and CV-related hospitalisations were lower in the continuous tafamidis vs placebo to tafamidis group (Figure B). Conclusions Continuous tafamidis treatment reduced mortality and hospitalisations (both all-cause and CV-related) across all NAC stages. These reductions were larger and occurred earlier in patients with NAC stage I, emphasising the importance of early disease-modifying treatment in patients with ATTR-CM.[3] NCT01994889, NCT02791230.
No takes yet. Share an insight, caveat, or question.
Damy et al. (2024) conducted an RCT in Transthyretin amyloid cardiomyopathy (ATTR-CM) (n=350). Continuous tafamidis vs. Placebo to tafamidis was evaluated on All-cause mortality (NAC stage I) (HR 0.43, 95% CI 0.26-0.70, p=<0.001). Continuous tafamidis reduced all-cause mortality vs placebo-to-tafamidis across NAC stages, with the largest reduction in stage I.
Synapse has enriched 10 related papers. Consider them for comparative context: